Key Milestones in Smoking Cessation by Achieve Life Sciences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a pioneering pharmaceutical company specializing in nicotine dependence, has recently announced significant advancements regarding the New Drug Application (NDA) for its primary drug, cytisinicline. This update marks an important step in their ongoing mission to aid individuals in quitting smoking.
Safety Update Submission to FDA
The company submitted a 120-day safety update to the U.S. Food and Drug Administration (FDA) to support the NDA review for cytisinicline. This comprehensive report includes crucial long-term safety data from a group of 411 participants who used cytisinicline for at least six months, and 214 participants who have been exposed to the drug for at least one year. This proactive step showcases Achieve Life Sciences’ commitment to proving the safety of its treatment.
Completion of the ORCA-OL Trial
Achieve has confirmed the completion of its ORCA-OL trial, a key study aimed at assessing the long-term safety of cytisinicline. The final participant completed their treatment, which comprised 334 individuals who underwent a full year of treatment. This outcome surpassed the FDA’s expectations for cumulative safety data, illustrating robust interest and participation in the study.
Data Safety Monitoring Committee Review
The Data Safety Monitoring Committee (DSMC) performed its fourth and final review of the ORCA-OL study. Their findings revealed that while some participants experienced adverse events, most were mild and not considered serious. This outcome further supports the assertion that cytisinicline is a safe and effective option for smoking cessation.
Insights from Achieve Life Sciences Leaders
Dr. Mark Rubinstein, the Interim Chief Medical Officer, shared, "Achieving these regulatory milestones and presenting our safety data to the FDA strengthens our confidence in cytisinicline as a viable treatment for nicotine dependence. We are aiming to deliver the first new FDA-approved treatment for smoking cessation in almost 20 years." This statement underscores the significance of these developments in the path toward regulatory approval.
Rick Stewart, CEO of Achieve Life Sciences, additionally commented on the trial’s impressive retention rate, stating, "The 334 participants who completed a year of treatment not only meet but exceed FDA requirements. This level of engagement speaks to the potential of cytisinicline in combating nicotine addiction."
About the ORCA-OL Trial
The ORCA-OL trial was meticulously designed to evaluate the long-term safety of cytisinicline, administered at a dosage of 3 mg, three times daily, for adults aged 18 and older. Conducted across 29 clinical sites, the trial successfully gathered extensive data to support the NDA process.
Overview of Achieve Life Sciences, Inc.
Founded with the mission to tackle nicotine dependence and its associated health challenges, Achieve Life Sciences has taken significant strides in the development of cytisinicline. In September 2025, the FDA accepted their NDA for this groundbreaking treatment, with a PDUFA date set for June 2026.
Fighting the Tobacco Epidemic
The smoking epidemic affects millions, with approximately 29 million adults in the U.S. alone still smoking combustible cigarettes. Tobacco use remains the leading cause of preventable death worldwide, highlighting the urgent necessity for effective cessation methods. Cytisinicline could play a crucial role in this battle, aiming to help individuals overcome nicotine addiction reliably and safely.
Cytisinicline's Mechanism of Action
Cytisinicline is a plant-derived alkaloid that exhibits significant binding activity at the nicotinic acetylcholine receptor. Its primary function is to alleviate nicotine cravings, potentially transforming the landscape of smoking cessation. Through its innovative approach, it helps mitigate the withdrawal symptoms and satisfaction associated with smoking.
Frequently Asked Questions
What is cytisinicline?
Cytisinicline is a treatment designed to aid individuals struggling with nicotine dependence, primarily for smoking cessation.
How has Achieve Life Sciences progressed with FDA?
The company has submitted safety updates and completed a critical trial, moving closer to NDA approval and a potential new treatment option.
What was the outcome of the ORCA-OL trial?
The ORCA-OL trial successfully exceeded required participation rates, showing a low incidence of serious side effects.
What's the significance of the 120-day safety update?
This update includes comprehensive long-term safety data crucial for the FDA's NDA review process for cytisinicline.
How does cytisinicline help with nicotine cravings?
By interacting with nicotine receptors in the brain, cytisinicline alleviates withdrawal symptoms and reduces the satisfaction derived from smoking.
